|
Aug 5
|
Here's Why Momentum in UCB (UCBJY) Should Keep going
|
|
Aug 5
|
UCB's HS Summit United Patients and Experts to Drive Progress in Hidradenitis Suppurativa Awareness and Treatment
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 18
|
Epilepsy Therapeutics Market Trends, Competitive Strategies and Forecasts Report 2025-2033 | Personalized Medicine Paves New Pathways in Treatment, Third-Generation Therapeutics Lead Growth
|
|
Jul 14
|
UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?
|
|
Jun 12
|
UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity
|
|
Jun 12
|
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
|
|
Jun 11
|
BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis
|
|
May 19
|
UCB and Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences
|
|
Oct 11
|
UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session
|
|
Sep 30
|
UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis
|
|
Sep 27
|
UCB Announces Late-Breaking Two-Year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024
|
|
Sep 25
|
UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024
|
|
Aug 29
|
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
|
|
Jul 29
|
UCB partners with Emmy Award winner Ben Decter and Tony Award nominee Kristin Hanggi in their heartfelt musical about living with epilepsy: It's All Your Fault, Tyler Price!
|
|
Jul 29
|
Prio And Two Other Stocks That May Be Priced Below Their Estimated Value
|
|
Jun 18
|
Top Value Stocks That Could Be Bargains In June 2024
|
|
Jun 13
|
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels
|
|
Jan 3
|
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive
|
|
Dec 2
|
UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting
|